Skip to main content

Table 3 Mutated genes across age of onset groups

From: Mutational landscape differences between young-onset and older-onset breast cancer patients

Gene

Young

Older

Oldest

p-value (young vs. older)

p-value (young vs. oldest)

TP53

31(34%)

320(33.6%)

133(28.6%)

0.91

0.32

PIK3CA

22(24%)

340(35.7%)

174(37.4%)

0.03*

0.02*

GATA3

20(22%)

123(12.9%)

50(10.8%)

0.02*

0.01*

TAF1

9(10%)

73(7.7%)

40(8.6%)

0.42

0.69

PTEN

7(8%)

58(6.1%)

32(6.9%)

0.50

0.82

NF1

6(7%)

97(10.2%)

57(12.3%)

0.36

0.15

ATM

6(7%)

70(7.4%)

35(7.5%)

1.00

1.00

MORC4

6(7%)

59(6.2%)

29(6.2%)

0.82

0.82

ARID1A

6(7%)

58(6.1%)

27(5.8%)

0.82

0.81

NIPBL

5(5%)

66(6.9%)

38(8.2%)

0.83

0.52

CTNNB1

5(5%)

14(1.5%)

10(2.2%)

0.02*

0.08

CDH1

4(4%)

170(17.9%)

96(20.6%)

0.0003*

0.0001*

PIK3R1

4(4%)

58(6.1%)

35(7.5%)

0.65

0.37

MAP2K4

4(4%)

53(5.6%)

26(5.6%)

0.81

0.80

RB1

4(4%)

49(5.1%)

23(4.9%)

1.00

1.00

PPP2R1A

4(4%)

34(3.6%)

23(4.9%)

0.57

1.00

AKT1

4(4%)

32(3.4%)

14(3%)

0.55

0.51

MAP3K1

3(3%)

108(11.3%)

66(14.2%)

0.01*

0.003*

BRCA1

3(3%)

47(4.9%)

26(5.6%)

0.61

0.60

CHD4

3(3%)

47(4.9%)

28(6%)

0.61

0.45

EP300

3(3%)

40(4.2%)

20(4.3%)

1.00

1.00

HCFC2

3(3%)

19(2%)

10(2.2%)

0.43

0.46

RPL22

3(3%)

13(1.4%)

9(1.9%)

0.16

0.43

RUNX1

2(2%)

62(6.5%)

33(7.1%)

0.11

0.10

FBXW7

2(2%)

33(3.5%)

16(3.4%)

0.76

0.75

ZC3H13

2(2%)

32(3.4%)

17(3.7%)

0.76

0.75

RASA1

2(2%)

31(3.3%)

16(3.4%)

1.00

0.75

CTCF

2(2%)

29(3%)

14(3%)

1.00

1.00

ACVR2A

2(2%)

28(2.9%)

17(3.7%)

1.00

0.75

ARID5B

2(2%)

26(2.7%)

18(3.9%)

1.00

0.76

SPOP

2(2%)

20(2.1%)

7(1.5%)

1.00

0.65

RNF43

2(2%)

14(1.5%)

11(2.4%)

0.64

1.00

TBX3

1(1%)

51(5.4%)

27(5.8%)

0.08

0.07

CCAR1

1(1%)

30(3.2%)

16(3.4%)

0.51

0.33

CASP8

1(1%)

26(2.7%)

14(3%)

0.50

0.48

LARP7

1(1%)

21(2.2%)

13(2.8%)

0.71

0.49

CDKN1B

1(1%)

13(1.4%)

6(1.3%)

1.00

1.00

RPL5

1(1%)

13(1.4%)

11(2.4%)

1.00

0.70

KRAS

1(1%)

12(1.3%)

8(1.7%)

1.00

1.00

CD3G

1(1%)

10(1.1%)

5(1.1%)

1.00

1.00

LATS1

1(1%)

10(1.1%)

6(1.3%)

1.00

1.00

CCND1

1(1%)

3(0.3%)

1(0.2%)

0.31

0.30

PIK3R3

0(0%)

18(1.9%)

12(2.6%)

0.39

0.23

PRRG1

0(0%)

13(1.4%)

10(2.2%)

0.62

0.38

B2M

0(0%)

8(0.8%)

4(0.9%)

1.00

1.00

AP1S1

0(0%)

7(0.7%)

5(1.1%)

1.00

1.00

  1. Frequency and proportion of patients in each age of onset group with mutations in 46 genes of interest. Entries are number of samples with at least one mutation in a given gene (% of samples in age of onset group). The genes of interest were selected based on Berger et al.’s study of gynecologic and breast cancers using TCGA data [30]. The p-values were calculated using a chi squared test for difference in proportions (* indicates statistical significance at the 0.05 level). Age of onset groups were defined as “Young”: breast tumours diagnosed ≤40 years of age (n = 91), “Older”: breast tumours diagnosed > 40 years of age (n = 952), and “Oldest”: breast tumours diagnosed > 60 years of age (n = 465). HER2+: human epidermal growth factor receptor 2 over-expressing